AlphaScreen®-Based characterization of the bifunctional kinase/ RNase IRE1α: A novel and atypical drug target

12Citations
Citations of this article
28Readers
Mendeley users who have this article in their library.

Abstract

Assay technologies that were originally developed for high-throughput screening (HTS) have recently proven useful in drug discovery for activities located upstream (target identification and validation) and downstream (ADMET) of HTS. Here the authors investigated and characterized the biological properties of a novel target, IRE1α, a bifunctional kinase/RNase stress sensor of the endoplasmic reticulum (ER). They have developed a novel assay platform using the HTS technology AlphaScreen® to monitor the dimerization/oligomerization and phosphorylation properties of the cytosolic domain of IRE1α. They show in vitro that dimerization/oligomerization of the cytosolic domain of IRE1 correlated with the autophosphorylation ability of this domain and its endoribonuclease activity toward XBP1 mRNA. Using orthogonal in vitro and cell-based approaches, the authors show that the results obtained using AlphaScreen®were biologically relevant. Preliminary characterization of assay robustness indicates that both AlphaScreen®assays should be useful in HTS for the identification of IRE 1 activity modulators © 2010 Society for Blomolecular Sciences.

Cite

CITATION STYLE

APA

Bouchecareilh, M., Caruso, M. E., Roby, P., Parent, S., Rouleau, N., Taouji, S., … Chevet, E. (2010). AlphaScreen®-Based characterization of the bifunctional kinase/ RNase IRE1α: A novel and atypical drug target. Journal of Biomolecular Screening, 15(4), 406–417. https://doi.org/10.1177/1087057110363823

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free